BACKGROUND: We previously demonstrated a decrease in bacterial vaginosis (BV) and an increase in Lactobacillus colonization among randomized controlled trial (RCT) participants who received monthly oral periodic presumptive treatment (PPT; 2 g metronidazole + 150 mg fluconazole). Posttrial data were analyzed to test the hypothesis that the treatment effect would persist after completion of 1 year of PPT. METHODS: Data were obtained from women who completed all 12 RCT visits and attended ≥ 1 posttrial visit within 120 days after completion of the RCT. We used Andersen-Gill proportional hazards models to estimate the posttrial effect of the intervention on the incidence of BV by Gram stain and detection of Lactobacillus species by culture. RESULTS: The analysis included 165 subjects (83 active and 82 placebo). The posttrial incidence of BV was 260 per 100 person-years in the intervention arm versus 358 per 100 person-years in the placebo arm (hazard ratio = 0.76; 95% confidence interval, 0.51-1.12). The posttrial incidence of Lactobacillus colonization was 180 per 100 person-years in the intervention arm versus 127 per 100 person-years in the placebo arm (hazard ratio = 1.42; 95% confidence interval, 0.85-2.71). CONCLUSIONS: Despite a decrease in BV and an increase in Lactobacillus colonization during the RCT, the effect of PPT was not sustained at the same level after cessation of the intervention. New interventions that reduce BV recurrence and promote Lactobacillus colonization without the need for ongoing treatment are needed.
RCT Entities:
BACKGROUND: We previously demonstrated a decrease in bacterial vaginosis (BV) and an increase in Lactobacillus colonization among randomized controlled trial (RCT) participants who received monthly oral periodic presumptive treatment (PPT; 2 g metronidazole + 150 mg fluconazole). Posttrial data were analyzed to test the hypothesis that the treatment effect would persist after completion of 1 year of PPT. METHODS: Data were obtained from women who completed all 12 RCT visits and attended ≥ 1 posttrial visit within 120 days after completion of the RCT. We used Andersen-Gill proportional hazards models to estimate the posttrial effect of the intervention on the incidence of BV by Gram stain and detection of Lactobacillus species by culture. RESULTS: The analysis included 165 subjects (83 active and 82 placebo). The posttrial incidence of BV was 260 per 100 person-years in the intervention arm versus 358 per 100 person-years in the placebo arm (hazard ratio = 0.76; 95% confidence interval, 0.51-1.12). The posttrial incidence of Lactobacillus colonization was 180 per 100 person-years in the intervention arm versus 127 per 100 person-years in the placebo arm (hazard ratio = 1.42; 95% confidence interval, 0.85-2.71). CONCLUSIONS: Despite a decrease in BV and an increase in Lactobacillus colonization during the RCT, the effect of PPT was not sustained at the same level after cessation of the intervention. New interventions that reduce BV recurrence and promote Lactobacillus colonization without the need for ongoing treatment are needed.
Authors: Sixto Sanchez; Patricia J Garcia; Katherine K Thomas; Mary Catlin; King K Holmes Journal: Am J Obstet Gynecol Date: 2004-12 Impact factor: 8.661
Authors: Jack D Sobel; Daron Ferris; Jane Schwebke; Paul Nyirjesy; Harold C Wiesenfeld; Jeffrey Peipert; David Soper; Suzanne E Ohmit; Sharon L Hillier Journal: Am J Obstet Gynecol Date: 2006-04-21 Impact factor: 8.661
Authors: Jeanne M Marrazzo; David H Martin; D Heather Watts; Joann Schulte; Jack D Sobel; Sharon L Hillier; Carolyn Deal; David N Fredricks Journal: Sex Transm Dis Date: 2010-12 Impact factor: 2.830
Authors: Catriona S Bradshaw; Anna N Morton; Jane Hocking; Suzanne M Garland; Margaret B Morris; Lorna M Moss; Leonie B Horvath; Irene Kuzevska; Christopher K Fairley Journal: J Infect Dis Date: 2006-04-26 Impact factor: 5.226
Authors: S L Hillier; R P Nugent; D A Eschenbach; M A Krohn; R S Gibbs; D H Martin; M F Cotch; R Edelman; J G Pastorek; A V Rao Journal: N Engl J Med Date: 1995-12-28 Impact factor: 91.245
Authors: Michael J Ferris; Alicia Masztal; Kenneth E Aldridge; J Dennis Fortenberry; Paul L Fidel; David H Martin Journal: BMC Infect Dis Date: 2004-02-13 Impact factor: 3.090
Authors: Jennifer E Balkus; Barbra A Richardson; Lorna K Rabe; Taha E Taha; Nyaradzo Mgodi; Margaret Phiri Kasaro; Gita Ramjee; Irving F Hoffman; Salim S Abdool Karim Journal: Sex Transm Dis Date: 2014-02 Impact factor: 2.830
Authors: Jennifer E Balkus; Sujatha Srinivasan; Omu Anzala; Joshua Kimani; Chloe Andac; Jane Schwebke; David N Fredricks; R Scott McClelland Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Erica M Lokken; Barbra A Richardson; John Kinuthia; Khamis Mwinyikai; Amina Abdalla; Walter Jaoko; Kishorchandra Mandaliya; Juma Shafi; R Scott McClelland Journal: Sex Transm Dis Date: 2019-01 Impact factor: 2.830
Authors: Anne Cc Lee; Luke C Mullany; Mohammad Quaiyum; Dipak K Mitra; Alain Labrique; Parul Christian; Parvez Ahmed; Jamal Uddin; Iftekhar Rafiqullah; Sushil DasGupta; Mahmoodur Rahman; Emilia H Koumans; Salahuddin Ahmed; Samir K Saha; Abdullah H Baqui Journal: Lancet Glob Health Date: 2019-01 Impact factor: 38.927
Authors: Arlene C Seña; Linda A Goldstein; Gilbert Ramirez; Austin J Parish; R Scott McClelland Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830